Generic Name and Formulations:
Aliskiren 150mg, 300mg; tabs.
Company:
Novartis Pharmaceuticals Corp
Hypertension.
≥18yrs: initially 150mg once daily, may increase to 300mg once daily if BP not adequately controlled. May be given with other antihypertensives (see literature).
<18yrs: not recommended.
Direct renin inhibitor.
Concomitant ARBs or ACEIs in diabetes.
Fetal toxicity may develop; discontinue if pregnancy is detected. Correct salt/volume depletion before starting therapy or start under close supervision. Moderate renal impairment (CrCl <60mL/min): avoid concomitant with ARBs or ACEIs. Impaired renal function: monitor serum creatinine periodically. Renal artery stenosis. Severe CHF. Monitor for hyperkalemia. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.
Concomitant cyclosporine, itraconazole: not recommended. Caution with ACEIs, ARBs, NSAIDs, K+ supplements, K+ sparing diuretics, K+ containing salt substitutes; may cause hyperkalemia. May be antagonized by, and renal toxicity potentiated by NSAIDs (including COX-2 inhibitors): monitor renal function in elderly and/or volume-depleted. Decreased absorption with high fat meals.
Diarrhea, hypotension, cough, rash, edema, elevated uric acid, gout, renal stones; rare: angioedema (discontinue if occurs; do not restart).
Tabs—30, 90